Summary.-In 3 years, 118 patients with Hodgkin's disease have completed chemotherapy with chlorambucil, vinblastine, procarbazine and prednisolone (ChlVPP).
IN 1975, we introduced the ChlVPP combination (chlorambucil, vinblastine, prednisolone and procarbazine) for the treatment of Hodgkin's disease. By replacing mustine (HN2) with chlorambucil, our aim was to provide treatment which was as effective as the original MOPP and MVPP combinations (De Vita et al., 1970; McElwain et al., 1973) , but would avoid the nausea and vomiting associated with HN2 administration.
The remission rates for the first 70 patients treated with Ch]VPP were equivalent to those obtained with HN2-containing combinations .
We now present data for remission rates in 118 patients, who completed treatment between July 1975 and December 1977. Three-year survival data are now available for the first 70 patients in the series, and these form the basis of the second part of this report.
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PATIENTS AND METHODS
Of 118 patients, 79 were male and 39 female. The mean age was 29-5 years (range 3-76).
Seventy-three patients were previously untreated, 29 had relapsed after prior radiotherapy, and 16 had relapsed after prior chemotherapy (with or without radiotherapy). Details of patients according to previous treatment are shown in Table I .
The Ann Arbor Staging Classification (Carbone et al., 1971 ) was used. Seventy-five patients were pathologically staged by laparotomy (Gazet, 1973) and 43 were staged clinically (McElwain et at., 1973 The number of courses is determined by the rate of response, as previously described .
In 42/73 previously untreated patients,
ChlVPP formed the first part of a combined chemotherapy-radiotherapy protocol.
The full rationale of this combined modality approach is given elsewhere . In essence, the patients are a group in whom by conventional criteria radiotherapy is indicated as primary treatment, but in whom cure with radiotherapy is infrequent (Peckham et al., 1975) . Our aim has been to improve the survival of these patients by treating them first with combination chemotherapy, and then, when remission has been achieved, to give the radiotherapy that would normally be indicated, for example "mantle" radiotherapy for patients with above-diaphragm Stage II disease or "total nodal" radiotherapy for those with Stage III disease.
Patients in this group included:
(a) The maximum follow-up on the 70 patients who formed the basis of the earlier report is now 46 months. Overall and disease-free survival rates for this group were measured from the date of starting chemotherapy, and were calculated by means of life-table analysis.
Twenty patients in the first 70 received elective radiotherapy in addition to ChlVPP as part of the combined-modality programme, and 23 patients received additional chemotherapy and/or radiotherapy because of progressive disease or later relapse. Twenty-seven patients had no additional treatment. (Figs. 3 & 4) . These results compare favourably with overall and disease-free survivals of 8300 and 71J respectively which were achieved by the patients receiving ChlVPP after relapse from primary treatment with radiotherapv (Figs. & 2) . Clearly, elective combinedmodality treatment is an effective way of increasing the survival of a group of patients whose prognosis after radiotherapy alone is poor, and giving the chemotherapy before the radiotherapy is a safe and convenient way of doing this. ._ 20 Fig. 5 . Excluding the 12 patients previously given chemotherapy, the difference between these 2 groups remains significant (P-0-01) and this confirms the prognostic importance of complete remission reported by Sutcliffe et al. (1978 
